Check for updates

#### **OPEN ACCESS**

EDITED BY Balaji Govindaswami, Valley Medical Center Foundation, United States

REVIEWED BY Matthew Nudelman, Marshall University, United States Rupalee Patel, Santa Clara Valley Medical Center, United States

\*CORRESPONDENCE Marine Lorenzi Marine.lorenzi@gmail.com

RECEIVED 06 April 2023 ACCEPTED 15 May 2023 PUBLISHED 02 June 2023

#### CITATION

Lorenzi M, Mayerus M, Eleni Dit Trolli S, Hue-Bigé A, Legueult K, Guellec-Renne I and François-Garret B (2023) An evaluation of the association between lockdown during the SARS-CoV-2 pandemic and prematurity at the Nice University Hospital. Front. Pediatr. 11:1201423. doi: 10.3389/fped.2023.1201423

#### COPYRIGHT

© 2023 Lorenzi, Mayerus, Eleni Dit Trolli, Hue-Bigé, Legueult, Guellec-Renne and François-Garret. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# An evaluation of the association between lockdown during the SARS-CoV-2 pandemic and prematurity at the Nice University Hospital

Marine Lorenzi<sup>1\*</sup>, Mathilde Mayerus<sup>1</sup>, Sergio Eleni Dit Trolli<sup>1</sup>, Amandine Hue-Bigé<sup>1</sup>, Kévin Legueult<sup>2</sup>, Isabelle Guellec-Renne<sup>1</sup> and Bérengère François-Garret<sup>1</sup>

<sup>1</sup>Department of Neonatology, Nice University Hospital, Nice, France, <sup>2</sup>Department of Clinical Research and Innovation (DRCI), Nice University Hospital, Nice, France

**Aim:** To study the association between lockdown in France due to the SARS-CoV-2 pandemic and premature births at the Nice University Hospital.

**Methods:** Data concerning neonates born at the level III maternity of the Nice University Hospital and immediately hospitalised in the neonatal reanimation unit or the neonatology department of the hospital with their mothers between the 1st of January 2017 and the 31st of December 2020, included.

**Results:** We did not find a significant decrease in the global number of premature births <37 weeks of gestation, in low weight at birth or a significant increase in stillbirths during lockdown compared to a period with no lockdown. The profiles of the mothers and their newborns were compared when birth occurred during lockdown vs. no lockdown.

**Conclusion:** We did not find any evidence of an association between lockdown and prematurity at the Nice University Hospital. This result is in agreement with meta-analyses published in the medical literature. The possible decrease in factors of risk of prematurity during lockdown is controversial.

#### KEYWORDS

SARS-CoV-2 pandemic, lockdown, prematurity, low weight at birth, stillbirth

# 1. Introduction

Prematurity is a major public health problem. Premature births represent 75% of perinatal mortality and more than half of infantile morbidity over the long term. Between 50,000 and 60,000 infants are born prematurely each year in France (1).

There are many factors of risk of prematurity. They can be related to obstetrical elements, maternal history and environmental factors. Some of the factors of risk changed during lockdown due to the SARS-CoV-2 virus, in particular imposed inactivity, atmospheric changes, changes to daily living and an increase in hygiene. France went into lockdown as of Tuesday 17th of March 2020 up to Sunday the 10th of May 2020, included. All nurseries, schools, universities have been closed as well as restaurant and business not essential. Outdoor gatherings, family or friendly reunions were no longer allowed. Teleworking has been promoted and barrier measures have been put in place (wearing a mask, social distancing, hygine promotion) (2).

The main aim of our study was to examine the association between lockdown and the birth of premature newborns in the general population at the level III maternity of the University Hospital of Nice.

# 2. Materials et methods

#### 2.1. Description of the study

An observational retrospective and monocentric study was performed at the neonatal reanimation unit and neonatal department of the University Hospital of Nice, a level III maternity.

The hospital's computer databases and written reports of biological results and hospitalisation were used to collect data.

#### 2.2. Criteria of inclusion

All newborns including full-term infants born at the University Hospital of Nice immediately admitted into the neonatal reanimation unit or neonatal department between the 1st of January 2017 and 31st of December 2020 were included (Figure 1).

#### 2.3. Data collection

The data included information concerning mothers and newborns. The information about the mother included: age, history of prematurity, injection of complete maturative antenatal corticosteroid therapy (two doses), antenatal administration of magnesium sulphate, mode of delivery (vaginal or caesarean) and the context of birth. The latter included risks of premature birth, premature rupture of membranes, vascular causes such as preeclampsia, metrorrhagia, suspicion of chorioamnionitis and other causes. The information about the newborn included: the weight and term of birth, the sex, administration of surfactant, the presence of broncho-pulmonary dysplasia defined as the need of supplementary oxygen for premature babies after 28 days of life, intra-ventricular hemorrage according to grade 3 (intraventricular hemorrage with dilation occupying more than 50% of the ventricule) and grade 4 Papile classification (intra-ventricular



hemorrage with associated parenchymal lesions) (3), periventricular leucomalacia determined by lesions of the periventricular white matter, ulcero-necrotic enterocolitis characteristic of necrosis of the digestive wall classified according to the modified Bell score (stage 2a and 3b) (4), retinopathy of prematurity characterised by a proliferative disorder of the vessels of the retina, patent ductus arteriosus, microbial infection identified with a sample (blood or cerebrospinal fluid culture) and the occurrence or not of death.

#### 2.4. Methods and statistical analysis

The total number of births and the term of the pregnancies were first analysed in a descriptive way from the 1st of January 2017 to the 31st of December 2020. The number of premature births and the weight of the newborns hospitalised per year was then noted. The incidence of prematurity, the low weights at birth and stillbirths were then compared for the period of lockdown vs. no lockdown. Finally, the profiles of the newborns and their mothers were compared during lockdown (from Tuesday 17th of March to Sunday 10th of May 2020, included) vs. the years 2017-2019 and vs. the date to date period (from 17th of March to the 10th of May for the years 2017, 2018 and 2019). We made comparisons with two different time periods to avoid seasonal variables. The descriptive analysis gave the frequencies and percentages for the qualitative variables as averages and standard deviations. The univariate analyses used the Pearson's chi-square test (or the Fisher's exact test) for qualitative variables and the Anova (or Kruskal-Wallis rank test) for quantitative variables where the mean is presented with range. Statistical analysis used R software (version 4.1.2). All tests were bilateral and a p-value <0.05 was considered as statistically significant.

## 2.5. Legal information

This study was referred to the « Comité d'Éthique pour les Recherches Non Interventionnelles ». A favourable response was obtained on the 1st of June 2021, agreement n°2021-034.

# 3. Results

Despite substantial variation in the number of hospital stays each month, fluctuation was random, a regular seasonal cycles was not observed (**Figure 2**). The number of premature births <37 weeks of gestation decreased continually each year in a non significant way, giving a lower frequency in 2020 (N=227). We found that this non significant decline was mainly related to « severely premature » newborns (N=59 in 2020 vs. N=92 in 2017, N=89 in 2018, N=76 in 2019). Significant variation in the weights of the newborns was found for the different periods (**Table 1**). We did not find a significant decrease in either the frequency of prematurity <37 weeks of gestation or low weights at birth during



lockdown compared to the average for 2017–2019 (p = 0.579 for term pregnancies, p = 0.392 for <1,000 g, p = 0.698 for <1,500 g) or date to date p = 0.689 for term pregnancies, p = 0.197 for <1,000 g, and p = 0.504 for <1,500 g). There was no significant increase in the number of stillborns during lockdown compared to no lockdown p > 0.99) (Table 2). When we compared the profiles of the mothers and newborns according to the term in lockdown vs. no lockdown we noted a significant decrease in the frequency of bronchopulmonary dysplasia of the severely premature, born before 28 weeks of gestation p = 0.049) but only when compared to the average for 2017–2019; this significant difference was not found when compared to the date to date period p = 0.076). In addition, the profiles of the mothers and newborns were comparable for the different periods (Tables 3, 4).

## 4. Discussion

This study did not reveal any evidence of a significant decrease in either prematurity or low birth weights during lockdown. There was no significant increase in the number of stillbirths. There was no significant difference in the profiles of the mothers or newborns. The collection of information is limited by the retrospective nature of the study since some of the data was missing or absent, which leads to a degree of bias regarding the information. Some of the absent information concerned maternal risk factors such as the preconception body mass index, the marital status, the economic status and level of education. In addition, the study lacked power due to the low number of individuals included, despite the collection of date over four years. Thus, the monocentric nature

	2017 ( <i>N</i> = 353)	2018 (N = 371)	2019 ( <i>N</i> = 364)	2020 ( <i>N</i> = 322)	Total ( <i>N</i> = 1410)	<i>p–</i> value
Term at birth	32.93 (24.00-42.00)	33.30 (24.00-42.00)	33.35 (24.00-42.00)	33.50 (23.00-42.00)	33.27 (23.00-42.00)	0.379
Grouped term at birth						0.143
<28 weeks	39 (11.0%)	43 (11.6%)	42 (11.5%)	36 (11.2%)	160 (11.3%)	
28-31 weeks	92 (26.1%)	89 (24.0%)	76 (20.9%)	59 (18.3%)	316 (22.4%)	
32-36 weeks	150 (42.5%)	143 (38.5%)	151 (41.5%)	132 (41.0%)	576 (40.9%)	
≥37 weeks	72 (20.4%)	96 (25.9%)	95 (26.1%)	95 (29.5%)	358 (25.4%)	
<28 weeks	39 (11.0%)	43 (11.6%)	42 (11.5%)	36 (11.2%)	160 (11.3%)	0.995
<32 weeks	131 (37.1%)	132 (35.6%)	118 (32.4%)	95 (29.5%)	476 (33.8%)	0.156
<37 weeks	281 (79.6%)	275 (74.1%)	269 (73.9%)	227 (70.5%)	1,052 (74.6%)	0.053
Birth weight (g)	1,920 (530.00-	2,030.35 (520.00-	2,006.61 (500.00-	2,062.57 (400.00-	2,004.09 (400.00-	0.209
	5,160.00)	5,302.00)	4,812.00)	4,508.00)	5,302.00)	
Birth weight (scale)						0.549
ELBW	42 (11.9%)	42 (11.3%)	49 (13.5%)	45 (14.0%)	178 (12.6%)	
VLBW	82 (23.3%)	76 (20.5%)	76 (20.9%)	52 (16.1%)	286 (20.3%)	
LBW	148 (42.0%)	151 (40.7%)	136 (37.4%)	131 (40.7%)	566 (40.2%)	
NBW	80 (22.7%)	102 (27.5%)	103 (28.3%)	94 (29.2%)	379 (26.9%)	

TABLE 1 Frequency of prematurity in the general population and birth weight of newborns hospitalised in the unit according to the year.

ELBW, extremely low birth weight <1,000 g; LBW, low birth weight <2,500 g; VLBW, very low birth weight <1,500 g; NBW, normal birth weight >2,500 g.

of the study does not allow generalisation of the results, which limits the external validity. However, the strength of the study lies in the exhaustive collection of hospitalised births admitted into the critical care neonatal unit and neonatology department of the Nice University Hospital during lockdown as well as the uniformity of the data and the collection of the number of stillborns. The number of stillborns was not different between periods and did not have an impact on prematurity.

The results are in agreement with some of the published literature and in particular with some meta-analyses concerning this subject, including the meta-analyses of Vaccaro et al. (5), Chmielewska et al. (6), and Yang et al. (7). Several studies showed that lockdown did not result in a decrease in prematurity, including in France (8), Spain (9), Sweden (10), Israel (11), the United States of America (12), the United Kingdom (13), and China (14). A meta-analysis by Vaccaro *et al.* evaluated the impact of lockdown on prematurity, low birth weight <2,500 g and stillbirths but did not report an association

between lockdown and these issues (5). Another meta-analysis by Chmielewska et al. did not find an association between lockdown and prematurity and low birth weight <2,500 g (6). A third meta-analysis by Yang et al. did not find any association between prematurity and lockdown in studies using regional/national data (7). In contrast, the initial published results were in favour of a decrease in prematurity and a low weight at birth during lockdown, notably by studies performed in spring of 2020 in Ireland (15) and Denmark (16). Other studies evaluating the association between prematurity, low birth weight and the number of stillborns performed around the world also found similar results, including in Iran (17), Australia (18), Saudi Arabia (19), Italy (20), Netherlands (21) and Austria (22). Two meta-analyses also demonstrated a decrease of prematurity during lockdown. Calvert et al. showed small reductions in preterm birth in high income and upper middle income countries during the first, second and third months of lockdown (but not in the fourth month) (23). Yao et al. identified a

	Lock	down vs. mean	of 2017–2019		L	.ockdown vs. da	te to date	
	Lockdown (N = 39)	No lockdown ( <i>N</i> = 1,088)	Total ( <i>N</i> = 1,127)	<i>p-</i> value	Lockdown (N = 39)	Lockdown ( <i>N</i> = 159)	Total ( <i>N</i> = 198)	<i>p-</i> value
Term at birth	33.59 (24.00-40.00)	33.20 (24.00-42.00)	33.21 (24.00-42.00)	0.579	33.59 (24.00-40.00)	33.26 (25.00-42.00)	33.33 (24.00-42.00)	0.689
<28 weeks	2 (5.1%)	124 (11.4%)	126 (11.2%)	0.222	2 (5.1%)	25 (15.7%)	27 (13.6%)	0.084
<32 weeks	12 (30.8%)	381 (35.0%)	393 (34.9%)	0.584	12 (30.8%)	54 (34.0%)	66 (33.3%)	0.705
<37 weeks	30 (76.9%)	825 (75.8%)	855 (75.9%)	0.875	30 (76.9%)	113 (71.1%)	143 (72.2%)	0.465
Sex				0.939				0.704
Boy	22 (56.4%)	95 (55.8%)	117 (55.8%)		22 (56.4%)	95 (59.7%)	117 (59.1%)	
Girl	17 (43.6%)	481 (44.2%)	498 (44.2%)		17 (43.6%)	64 (40.3%)	81 (40.9%)	
Weight <1,000 g	3 (7.7%)	133 (12.2%)	136 (12.1%)	0.392	3 (7.7%)	101 (63.5%)	128 (64.6%)	0.197
Weight <1,500 g	12 (30.8%)	367 (33.8%)	379 (33.7%)	0.698	12 (30.8%)	58 (36.5%)	70 (35.4%)	0.504
				>0.99				>0.99
Nb of total births	452	9,729	10,181		452	1,383	1,835	
Nb of stillborns	9	261	270		9	31	40	

TABLE 2 Incidence of prematurity, sex, weight and number of stillborns during lockdown (from Tuesday 17th of March to Sunday 10th of May 2020) vs. mean of 2017–2019 and date to date (from the 17th of March to the 10th of May of years 2017, 2018 and 2019).

Nb, number.

TABLE 3 Profiles of the mothers and newborns by term during lockdown (from Tuesday 17th of March 2020 to Sunday 10th of May 2020 included) vs. mean of 2017-2019.

Frontiers in Pediatrics

								ĺ				
		<28 wee	ks			28-31±6 w	eeks			32-36±6 w	eeks	
	Lockdown (N=2)	No lockdown (N= 124)	Total (N = 126)	<i>p-</i> value	Lockdown (N=10)	No lockdown (N=257)	Total (N= 267)	<i>p</i> - value	Lockdown (N = 18)	No lockdown (N = 444)	Total ( <i>N</i> = 462)	<i>p-</i> value
Characteristics of mothers and r	newborns											
Sex				0.782				0.804				0.885
Boy	1 (50%)	74 (59.7%)	75 (59.5%)		6 (60.0%)	144 (56.0%)	150 (56.2%)		10 (55.6%)	239 (53.8%)	249 (53.9%)	
Girl	1 (50%)	50 (40.3%)	51 (40.5%)		4 (40.0%)	113 (44.0%)	117 (43.8%)		8 (44.4%)	205 (46.2%)	213 (46.1%)	
Mother's age	34 (27.00- 41.00)	31.03 (19.00– 44.00)	31.08 (19.00– 44.00)	0.446	33.30 (25.00– 41.00)	31.44 (18.00– 56.00)	31.51 (18.00- 56.00)	0.340	33.35 (24.00– 44.00)	31.62 (16.00– 49.00)	31.68 (16.00– 49.00)	0.232
Premature birth history	0 (0.0%)	12 (9.8%)	12 (9.7.%)	0.641	3 (30.0%)	17 (6.7%)	20 (7.5.%)	0.006	4 (22.2%)	26 (5.9%)	30 (6.5%)	0.007
History of fetal death <i>in utero</i>	0 (0.0%)	5 (4.1%)	5 (4.0%)	0.538	0 (0.0%)	7 (2.7%)	7 (2.6%)	0.503	0 (0.0%)	16 (3.6%)	16 (3.5%)	060.0
Complete antenatal corticosteroid	2 (100%)	84 (67.7%)	86 (68.3%)	1	6 (60.0%)	205 (80.1%)	211 (73.9%)	0.270	9 (50.0%)	259 (58.3%)	268 (58.0%)	0.745
therapy												
Magnesium sulfate	1 (50.0%)	104 (83.9%)	105 (83.3%)	0.202	10 (100.0%)	208 (81.2%)	218 (82.0%)	0.130	4 (22.2%)	72 (16.2%)	76 (16.5%)	0.503
Group B Streptococcus testing				0.642				0.681				0.845
Negative	2 (100.0%)	85 (69.1%)	87 (69.6%)		7 (70.0%)	157 (61.1%)	164 (61.4%)		12 (66.7%)	305 (68.7%)	317 (68.6%)	
Positive	0 (0.0%)	14 (11.4%)	14 (11.2%)		0 (0.0%)	16 (6.2%)	16 (6.0%)		1 (5.6%)	35 (7.8%)	36 (7.8%)	
Not done	0 (0.0%)	24 (19.5%)	24 (19.2%)		3 (30.0%)	84 (32.7%)	87 (32.6%)		5 (27.8%)	100 (22.5%)	105 (22.7%)	
Perinatal context				0.857				0.545				0.766
Threat of premature labor	1 (50.0%)	59 (47.6%)	60 (47.6%)		4 (40.0%)	64 (24.9%)	68 (25.5%)		5 (27.8%)	97 (21.8%)	102 (22.1%)	
PPROM	0 (0.0%)	25 (20.2%)	25 (19.8%)		0 (0.0%)	45 (17.5%)	45 (16.9%)		5 (27.8%)	135 (30.4%)	140 (30.3%)	
Pre-eclampsia/vascular	0 (0.0%)	13 (10.5%)	13 (10.3%)		4 (40.0%)	72 (28.0%)	76 (28.5%)		7 (38.9%)	132 (29.7%)	139 (30.1%)	
Metrorrhagia	0 (0.0%)	4 (3.2%)	4 (3.2%)		0 (0.0%)	9 (3.5%)	9 (3.4%)		0 (0.0%)	18 (4.1%)	18 (3.9%)	
Chorio amnionitis	1 (50.0%)	21 (16.9%)	22 (17.5%)		2 (20.0%)	52 (20.2%)	54 (20.2%)		0 (0.0%)	16 (3.6%)	16 (3.5%)	
Other	0 (0.0%)	2 (1.6%)	2 (1.6%)		0 (0.0%)	15 (5.8%)	15 (5.6%)		1 (5.6%)	46 (10.4%)	47 (10.2%)	
Delivery route				0.873				0.126				0.581
Vaginal	1 (50.0%)	69 (55.6%)	70 (55.6%)		6 (60.0%)	93 (36.2%)	99 (37.1%)		7 (38.9%)	202 (45.5%)	209 (45.2%)	
Caesarean section	1 (50.0%)	55 (44.4%)	56 (44.4%)		4 (40.0%)	164 (63.8%)	168 (62.9%)		11 (61.1%)	242 (54.5%)	253 (54.8%)	
Perinatal outcomes												
Respiratory distress syndrome	2 (100.0%)	124 (100.0%)	126 (100.0%)	1	10 (100.0%)	240 (93.4%)	250 (93.6%)	0.401	8 (44.4%)	198 (44.6%)	206 (44.6%)	066.0
Surfactant	2 (100.0%)	85 (68.5%)	87 (69.0%)	0.340	5 (50.0%)	59 (23.0%)	64 (24.0%)	0.049	0 (0.0%)	17 (3.8%)	17 (3.7%)	0.398
Bronchopulmonary dysplasia	0 (0.0%)	82 (66.7%)	82 (65.6%)	0.049	3 (30.0%)	52 (20.2%)	55 (20.6%)	0.454	0 (0.0%)	2 (0.5%)	2 (0.4%)	0.775
Intraventicular hemorrhage	1 (50.0%)	51 (41.1%)	52 (41.3%)	0.800	1 (10.0%)	37 (14.4%)	38 (14.2%)	0.696	1 (5.6%)	38 (8.6%)	39 (8.4%)	0.651
Periventricular leukomalacia	0 (0.0%)	4 (3.2%)	4 (3.2%)	0.497	1 (10.0%)	4 (1.6%)	5 (1.9%)	0.142	0 (0.0%)	2 (0.5%)	2 (0.4%)	0.069
Necrotizing enterocolitis	0 (0.0%)	13 (10.5%)	13 (10.3%)	0.629	0 (0.0%)	6 (2.3%)	6 (2.2%)	0.625	0 (0.0%)	5 (1.1%)	5 (1.1%)	0.651
Neonatal infection	0 (0.0%)	40 (32.3%)	40 (31.7%)	0.591	0 (0.0%)	32 (12.5%)	32 (12.0%)	0.312	0 (0.0%)	12 (2.7%)	12 (2.6%)	0.413
Retinopathy	0 (0.0%)	6 (4.8%)	6 (4.8%)	0.909	0 (0.0%)	0 (0.0%)	0 (0.0%)	I	0 (0.0%)	0 (0.0%)	0 (0.0%)	I
Ductus arteriosus	0 (0.0%)	67 (54.0%)	67 (54.0%)	0.122	1 (10.0%)	20 (7.8%)	21 (7.9%)	0.798	2 (11.1%)	5 (1.1%)	7 (1.5%)	<0.001
Death	1 (50.0%)	34 (27.4%)	35 (27.8%)	0.479	2 (20.0%)	13 (5.1%)	15 (5.6%)	0.044	1 (5.6%)	10 (2.3%)	11 (2.4%)	0.367
PPROM, preterm premature rupture c p value < 0.05 was consider statistical	of the membrane Ily significant.	es.										

~	
011	
Ñ	
ar	
Ş	
ð	
lay	
₹	
Ö	
G	
E C	
ţ	
ę	
- S	
arc	
Σ	
ç	
ť	
E	
the	
Ē	
ro	
e E	
late	
0	
e t	
late	
0	
( <s< td=""><td></td></s<>	
20]	
20	
Ň	
ž	
of	
ţ	
9	
ay	
nd	
Su	
ç	
0	
000	
4	
arc	
ž	
of	
ť	
1	
ay	
sd	
ľ	
Ē	
ō	
f	
Ň	
90	
ž	
2	
ing	
luring	
n during	
erm during	
y term during	
s by term during	
rns by term during	
borns by term during.	
ewborns by term during	
1 newborns by term during	
and newborns by term during	
rs and newborns by term during	
hers and newborns by term during	
others and newborns by term during	
mothers and newborns by term during	
the mothers and newborns by term during	
of the mothers and newborns by term during	
es of the mothers and newborns by term during	
files of the mothers and newborns by term during	129).
Profiles of the mothers and newborns by term during	2019).
4 Profiles of the mothers and newborns by term during	nd 2019).
.E 4 Profiles of the mothers and newborns by term during	3 and 2019).
ABLE 4 Profiles of the mothers and newborns by term during	018 and 2019).

Frontiers in Pediatrics

			<28 weeks				28–31 ± 6 wee	eks			32-36±6 wee	iks	
A model of a model o		Lockdown (N= 2)	No lockdown (N = 25)	Total (N= 27)	<i>p-</i> value	Lockdown (N= 10)	No lockdown (N=29)	Total (N = 39)	<i>p-</i> value	Lockdown (N = 18)	No lockdown (N=59)	Total (N = 77)	<i>p-</i> value
state <tt< td=""><td>Characteristics of mothers ar</td><td>nd newborns</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tt<>	Characteristics of mothers ar	nd newborns											
Byty Cytolog C	Sex				0.957				0.754				0.922
Gal 1 (35 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.1 %) 3 (4.	Boy	1 (50%)	13 (52.0%)	14 (51.9%)		6 (60.0%)	19 (65.5%)	25 (64.1%)		10 (55.6%)	32 (54.2%)	42 (54.5%)	
Onder spec Open of a constraint constraint of a constraint constraint of a constraint	Girl	1 (50%)	12 (48.0%)	13 (48.1%)		4(40.0%)	10 (34.5%)	14 (35.9%)		8 (44.4%)	27 (45.8%)	35 (45.5%)	
Frommer bin binory (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00)	Mother's age	34 (27.00– 41.00)	31.80 (21.00-41.00)	31.96 (21.00- 41.00)	0.654	33.30 (25.00- 41.00)	29.59 (23.00–38.00)	30.54 (23.00- 41.00)	0.037	33.35 (24.00– 44.00)	32.44 (19.00-43.00)	32.65 (19.00- 44.00)	0.566
Histor eff all darby area 0 (0,0) 0 (0,0) 0 (0,0) 0 (0,0) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50) 1 (1,50)	Premature birth history	0 (0.0%)	2 (8.0%)	2 (7.4.%)	0.678	3 (30.0%)	1 (3.4%)	4 (10.3.%)	0.017	4 (22.2%)	6 (10.1%)	10 (13.0%)	0.203
Complex memory 2 (00%) 16 (4.0%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%) 18 (6.4%)	History of fetal death in utero	0 (0.0%)	0 (0.0%)	0 (0.0%)	1	0 (0.0%)	1 (3.4%)	1 (2.6%)	1	0 (0.0%)	1 (1.7%)	1 (1.3%)	0.656
Mergenion solito: Carey R Sequence tracting1 (54)(6)1 (8 (72.6))1 (8 (73.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1 (2 (71.6))1	Complete antenatal corticosteroid therapy	2 (100%)	16 (64.0%)	18 (66.7%)	I	6 (60.0%)	20 (69.0%)	26 (66.7%)	0.868	9 (50.0%)	38 (64.4%)	47 (61.0%)	0.441
Goup Streptoconstreting ···· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···<	Magnesium sulfate	1 (50.0%)	18 (72.0%)	19 (70.4%)	0.512	10 (100.0%)	23 (79.3%)	33 (84.6%)	0.118	4 (22.2%)	12 (20.3%)	16 (20.8%)	0.863
Nagaine 2 (100%) 16 (640%) 18 (66.%) 18 (66.%) 18 (66.%) 18 (66.%) 18 (65.%) 18 (65.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 18 (55.%) 1	Group B Streptococcus testing				0.618				0.419				0.926
Detine 0 (00%) 4 (16/%) 4 (16/%) 1 (16/%) 1 (16/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%) 2 (6/%)	Negative	2 (100.0%)	16 (64.0%)	18 (66.7%)		7 (70.0%)	14 (48.3%)	21 (53.8%)		12 (66.7%)	34 (57.6%)	46 (59.8%)	
Not due 0 (00%) 4 (16%) 4 (16%) 2 (3.0%) 1 (4.1%) 2 (3.0%) 2 (3.2%) 1 (7.3%) 2 (2.3%) 2 (2.3%) 2 (2.3%) 2 (2.3%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) 2 (3.5%) <th< td=""><td>Positive</td><td>0 (0.0%)</td><td>4 (16.0%)</td><td>4 (16.0%)</td><td></td><td>0 (0.0%)</td><td>2 (6.9%)</td><td>2 (5.1%)</td><td></td><td>1 (5.6%)</td><td>4 (6.7%)</td><td>5 (6.5%)</td><td></td></th<>	Positive	0 (0.0%)	4 (16.0%)	4 (16.0%)		0 (0.0%)	2 (6.9%)	2 (5.1%)		1 (5.6%)	4 (6.7%)	5 (6.5%)	
Primal contact ···· ···· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ···< ··· ··· ··· ··· ···< ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ··· ···< ··· ···	Not done	0 (0.0%)	4 (16.0%)	4 (16.0%)		3 (30.0%)	13 (44.8%)	16 (41.0%)		5 (27.8%)	17 (28.8%)	22 (28.6%)	
	Perinatal context				1				0.588				0.184
PROM0 (00%)1 (40%)1 (3.5%)1 (3.5%)1 (1.3%)1 (1.3%)2 (1.3%)2 (4.0%)2 (3.5%)2 (4.0%)2 (3.5%)2 (4.0%)2 (3.5%)2 (4.0%)2 (3.5%)2 (4.0%)2 (3.5%)2 (4.0%)2 (3.5%)2 (4.0%)2 (3.5%)2 (4.0%)2 (3.5%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)2 (4.0%)	Threat of premature labor	1 (50.0%)	13 (52.0%)	14 (51.9%)		4 (40.0%)	10 (34.5%)	14 (35.9%)		5 (27.8%)	4 (6.8%)	9 (11.7%)	
Pre-clunpsiarvacular $0 (00\%)$ $2 (30\%)$ $2 (74\%)$ $4 (400\%)$ $8 (27\%)$ $8 (27\%)$ $2 (38\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$ $2 (35\%)$	PPROM	0 (0.0%)	1 (4.0%)	1 (3.7%)		0 (0.0%)	4 (13.8%)	4 (10.3%)		5 (27.8%)	24 (40.7%)	29 (37.7%)	
	Pre-eclampsia/vascular	0 (0.0%)	2 (8.0%)	2 (7.4%)		4(40.0%)	8 (27.6%)	12 (30.8%)		7 (38.9%)	21 (35.6%)	28 (36.4%)	
Chorio aminotitis $1 (50.0\%)$ $8 (32.0\%)$ $8 (32.0\%)$ $2 (33.3\%)$ $2 (2.0\%)$ $3 (10.3\%)$ $3 (1.3\%)$ $3 (1.3\%)$ $3 (1.3\%)$ $3 (3.1\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 (3.9\%)$ $3 $	Metrorrhagia	0 (0.0%)	1 (4.0%)	1 (3.7%)		0 (0.0%)	3 (10.3%)	3 (7.7%)		0 (0.0%)	2 (3.4%)	2 (2.6%)	
Other $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $1 (3.4\%)$ $1 (3.6\%)$ $5 (3.5\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$ $6 (7.8\%)$	Chorio amnionitis	1 (50.0%)	8 (32.0%)	9 (33.3%)		2 (20.0%)	3 (10.3%)	5 (12.8%)		0 (0.0%)	3 (5.1%)	3 (3.9%)	
Delivery route image	Other	0 (0.0%)	0 (0.0%)	0 (0.0%)		0 (0.0%)	1 (3.4%)	1 (2.6%)		1 (5.6%)	5 (8.5%)	6 (7.8%)	
Vaginal $1 (50.0\%)$ $14 (56.0\%)$ $15 (55.6\%)$ $5 (60.0\%)$ $8 (27.6\%)$ $14 (35.9\%)$ $2 (39.0\%)$ $2 (39.0\%)$ $2 (39.0\%)$ $2 (39.0\%)$ $2 (39.0\%)$ $2 (39.0\%)$ $2 (39.0\%)$ $2 (39.0\%)$ $2 (51.0\%)$ $2 (51.0\%)$ $2 (51.0\%)$ $2 (51.0\%)$ $2 (51.0\%)$ $2 (51.0\%)$ $2 (51.0\%)$ $2 (51.0\%)$ $2 (51.0\%)$ $2 (51.0\%)$ $2 (51.0\%)$ $2 (51.0\%)$ $2 (51.0\%)$ $2 (51.0\%)$ $2 (51.0\%)$ $2 (51.0\%)$ $2 (51.0\%)$ $2 (51.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21.0.0\%)$ $2 (21$	Delivery route				0.869				0.065				0.994
Caeaarea section1 (500%)11 (44.0%)12 (44.4%)12 (44.4%)24 (40.0%)24 (40.0%)24 (40.0%)24 (40.0%)24 (40.0%)24 (61.0%)36 (61.0%)36 (61.0%)47 (61.0%)36 (61.0%)36 (61.0%)36 (61.0%)36 (61.0%)36 (61.0%)36 (61.0%)36 (61.0%)36 (61.0%)36 (61.0%)36 (61.0%)36 (61.0%)36 (61.0%)36 (61.0%)36 (61.0%)36 (61.0%)36 (61.0%)36 (61.0%)36 (61.0%)36 (61.0%)36 (61.0%)36 (61.0%)31 (40.3%)36 (61.0%)31 (40.3%)36 (61.0%)31 (40.3%)36 (61.0%)31 (40.3%)36 (61.0%)31 (40.3%)36 (61.0%)31 (40.3%)36 (61.0%)31 (40.3%)36 (61.0%)31 (40.3%)36 (61.0%)31 (40.3%)36 (61.0%)31 (40.3%)36 (61.0%)31 (40.3%)36 (61.0%)31 (40.3%)36 (61.0%)31 (41.3%)36 (61.0%)31 (41.3%)36 (61.0%)31 (41.3%)36 (61.0%)31 (41.3%)36 (61.0%)31 (41.3%)36 (61.0%)31 (41.3%)36 (61.0%)31 (41.3%)36 (61.0%)31 (41.3%)36 (61.0%)31 (41.3%)36 (61.0%)31 (41.3%)36 (61.0%)31 (41.3%)36 (61.0%)31 (41.3%)36 (61.0%)31 (41.3%)36 (61.0%)31 (41.3%)36 (61.0%)31 (41.3%)36 (61.0%)31 (41.3%)36 (61.0%)31 (41.3%)36 (61.0%)31 (41.3%)36 (61.0%)31 (41.3%)36 (61.0%)31 (41.3%)36 (61.0%)31 (41.3%)36 (61.0%)31 (41.3%)36 (61.0%)31 (41.3%)36 (61.0%)31 (41.3%)36 (61.0%) </td <td>Vaginal</td> <td>1 (50.0%)</td> <td>14 (56.0%)</td> <td>15 (55.6%)</td> <td></td> <td>6 (60.0%)</td> <td>8 (27.6%)</td> <td>14 (35.9%)</td> <td></td> <td>7 (38.9%)</td> <td>23 (39.0%)</td> <td>30 (39.0%)</td> <td></td>	Vaginal	1 (50.0%)	14 (56.0%)	15 (55.6%)		6 (60.0%)	8 (27.6%)	14 (35.9%)		7 (38.9%)	23 (39.0%)	30 (39.0%)	
<b>Primate outcomes</b> Repirated outcomes   Repiratory distress syndrome 2 (100.0%) 25 (100.0%) 27 (100.0%) 27 (100.0%) 31 (40.3%) 0.195 0.444.%) 23 (39.0%) 31 (40.3%) 0.578   Repiratory distress syndrome 2 (100.0%) 17 (68.0%) 19 (70.4%) 0.340 5 (50.0%) 8 (27.6%) 13 (33.3%) 0.195 0 (0.0%) 1 (1.7%) 1 (1.3%) 0.578   Bronchopulmonary dysplasia 0 (00%) 16 (64.0%) 14 (40.7%) 0.340 5 (7.2%) 8 (25.6%) 0.968 0 (0.0%) 1 (1.7%) 1 (1.3%) 0.578   Bronchopulmonary dysplasia 0 (00%) 16 (64.0%) 0.782 1 (10.0%) 5 (17.2%) 8 (25.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0	Caesarean section	1 (50.0%)	11 (44.0%)	12 (44.4%)		4(40.0%)	21 (72.4%)	25 (64.1%)		11 (61.1%)	36 (61.0%)	47 (61.0%)	
Respiratory distress syndrome $27(1000\%)$ $27(1000\%)$ $27(1000\%)$ $27(91,00\%)$ $27(91,00\%)$ $27(91,00\%)$ $27(91,00\%)$ $21(91,00\%)$ $21(91,00\%)$ $21(91,00\%)$ $21(91,00\%)$ $21(91,00\%)$ $21(91,00\%)$ $21(91,00\%)$ $21(91,00\%)$ $21(91,00\%)$ $21(91,00\%)$ $21(91,00\%)$ $21(91,00\%)$ $21(91,00\%)$ $21(91,00\%)$ $21(91,00\%)$ $21(91,00\%)$ $21(91,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ $21(11,00\%)$ <th< td=""><td>Perinatal outcomes</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>	Perinatal outcomes												
Surfactant $2 (100.0\%)$ $17 (68.0\%)$ $19 (70.4\%)$ $19 (70.4\%)$ $5 (50.0\%)$ $8 (27.6\%)$ $13 (33.3\%)$ $0.195$ $0 (00\%)$ $1 (1.7\%)$ $1 (1.3\%)$ $0.55$ Bronchopulmonary dysplasia $0 (0.0\%)$ $16 (64.0\%)$ $16 (59.3\%)$ $0.76$ $3 (30.0\%)$ $5 (172.\%)$ $8 (20.5\%)$ $0.968$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0$	Respiratory distress syndrome	2 (100.0%)	25 (100.0%)	27 (100.0%)	1	10 (100.0%)	27 (93.1%)	37 (94.9%)	0.394	8 (44.4%)	23 (39.0%)	31 (40.3%)	0.679
Bronchopulmonary dysplasia $0(00\%)$ $16(640\%)$ $16(53.\%)$ $0.076$ $3(00\%)$ $5(17.2\%)$ $8(20.5\%)$ $0.968$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ $0(00\%)$ <th< td=""><td>Surfactant</td><td>2 (100.0%)</td><td>17 (68.0%)</td><td>19 (70.4%)</td><td>0.340</td><td>5 (50.0%)</td><td>8 (27.6%)</td><td>13 (33.3%)</td><td>0.195</td><td>0 (0.0%)</td><td>1 (1.7%)</td><td>1 (1.3%)</td><td>0.578</td></th<>	Surfactant	2 (100.0%)	17 (68.0%)	19 (70.4%)	0.340	5 (50.0%)	8 (27.6%)	13 (33.3%)	0.195	0 (0.0%)	1 (1.7%)	1 (1.3%)	0.578
Intraventicular hemorrhage $1 (50\%)$ $10 (400\%)$ $11 (40.7\%)$ $0.782$ $1 (100\%)$ $5 (17.2\%)$ $6 (15.4\%)$ $0.584$ $1 (56\%)$ $5 (8.5\%)$ $6 (7.8\%)$ $0.66$ Periventicular hemorrhage $0 (00\%)$ $0 (00\%)$ $0 (00\%)$ $0 (00\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0$	Bronchopulmonary dysplasia	0 (0.0%)	16 (64.0%)	16 (59.3%)	0.076	3 (30.0%)	5 (17.2%)	8 (20.5%)	0.968	0 (0.0%)	0 (0.0%)	0 (0.0%)	I
Periventricular leukomalacia 0 (0.0%) 0 (0.0%) - 1 (10.0%) 1 (3.4%) 2 (5.1%) 0.31 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) <td>Intraventicular hemorrhage</td> <td>1 (50.0%)</td> <td>10 (40.0%)</td> <td>11 (40.7%)</td> <td>0.782</td> <td>1 (10.0%)</td> <td>5 (17.2%)</td> <td>6 (15.4%)</td> <td>0.584</td> <td>1 (5.6%)</td> <td>5 (8.5%)</td> <td>6 (7.8%)</td> <td>0.686</td>	Intraventicular hemorrhage	1 (50.0%)	10 (40.0%)	11 (40.7%)	0.782	1 (10.0%)	5 (17.2%)	6 (15.4%)	0.584	1 (5.6%)	5 (8.5%)	6 (7.8%)	0.686
Nectotizing enterocolitis $0 (0.0\%)$ $3 (12.0\%)$ $3 (11.1\%)$ $0.603$ $0.60\%$ $0 (0.0\%)$ $ 0 (0.0\%)$ $ 0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $ 0 (0.0\%)$ $ 0 (0.0\%)$ $ 0 (0.0\%)$ $  0 (0.0\%)$ $ 0 (0.0\%)$ $                                                                                                                                      -$ <t< td=""><td>Periventricular leukomalacia</td><td>0 (0.0%)</td><td>0 (0.0%)</td><td>0 (0.0%)</td><td>I</td><td>1 (10.0%)</td><td>1 (3.4%)</td><td>2 (5.1%)</td><td>0.331</td><td>0 (0.0%)</td><td>0 (0.0%)</td><td>0 (0.0%)</td><td>I</td></t<>	Periventricular leukomalacia	0 (0.0%)	0 (0.0%)	0 (0.0%)	I	1 (10.0%)	1 (3.4%)	2 (5.1%)	0.331	0 (0.0%)	0 (0.0%)	0 (0.0%)	I
Neonatal infection 0 (0.0%) 10 (40.0%) 10 (37.0%) 0.501 0 (0.0%) 2 (5.1%) 0.355 0 (0.0%) 1 (1.7%) 1 (1.3%) 0.556   Retinopathy 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) - 0 (0.0%) - 0 (0.0%) - 0 (0.0%) - 0 (0.0%) - 0 (0.0%) - 0 (0.0%) - 0 (0.0%) - 0 (0.0%) - 0 (0.0%) - 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) <td>Necrotizing enterocolitis</td> <td>0 (0.0%)</td> <td>3 (12.0%)</td> <td>3 (11.1%)</td> <td>0.603</td> <td>0 (0.0%)</td> <td>0 (0.0%)</td> <td>0 (0.0%)</td> <td>I</td> <td>0 (0.0%)</td> <td>0 (0.0%)</td> <td>0 (0.0%)</td> <td>I</td>	Necrotizing enterocolitis	0 (0.0%)	3 (12.0%)	3 (11.1%)	0.603	0 (0.0%)	0 (0.0%)	0 (0.0%)	I	0 (0.0%)	0 (0.0%)	0 (0.0%)	I
Retinopathy 0 (0.0%) 0 (0.0%) 0 (0.0%) - 0 (0.0%) 0 (0.0%) - 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.	Neonatal infection	0 (0.0%)	10 (40.0%)	10 (37.0%)	0.501	0 (0.0%)	2 (6.9%)	2 (5.1%)	0.395	0 (0.0%)	1 (1.7%)	1 (1.3%)	0.576
Ductus arteriosus 0 (0.0%) 14 (56.0%) 14 (51.9%) 0.127 1 (10.0%) 1 (3.4%) 2 (5.1%) 0.418 2 (11.1%) 1 (1.7%) 3 (3.9%) 0.001   Death 1 (50.0%) 8 (32.0%) 9 (33.3%) 0.603 2 (20.0%) 1 (3.4%) 3 (7.7%) 0.090 1 (5.6%) 0 (0.0%) 1 (1.3%) 2 (3.9%) 0.068	Retinopathy	0 (0.0%)	0 (0.0%)	0 (0.0%)	I	0 (0.0%)	0 (0.0%)	0 (0.0%)	I	0 (0.0%)	0 (0.0%)	0 (0.0%)	I
Death 1 (50.0%) 8 (32.0%) 9 (33.3%) 0.603 2 (20.0%) 1 (3.4%) 3 (7.7%) 0.090 1 (5.6%) 0 (0.0%) 1 (1.3%) 0.068	Ductus arteriosus	0 (0.0%)	14 (56.0%)	14 (51.9%)	0.127	1 (10.0%)	1 (3.4%)	2 (5.1%)	0.418	2 (11.1%)	1 (1.7%)	3 (3.9%)	0.071
	Death	1 (50.0%)	8 (32.0%	9 (33.3%)	0.603	2 (20.0%)	1 (3.4%)	3 (7.7%)	060.0	1 (5.6%)	0 (0.0%)	1 (1.3%)	0.068
	<i>p</i> value < 0.05 was consider statis	tically significant.											

06

reduction in preterm birth during pandemic compared with pre pandemic period, but further subgroup analysis showed that there were no difference in studies from multicenter or low and middle income countries (24). According to these studies the potential positive effects of lockdown on prematurity and low birth weight were due to several factors. These included the decrease in social interaction, the shutdown of schools, the waring of masks and an increase in hygiene, which may have decreased the risk of contact with pathogens and thus a decrease in maternal infection (15–21).

There are many factors of risk of prematurity but the ethology is sometimes not well understood. They can be maternal, obstetric, infectious or environmental. The factors of risk of prematurity that may have changed during lockdown include atmospheric pollution (due to limited journeys), rest and maternal stress (with more time at home, the set up of work from home, more family support with the partner at home and certain financial assistance from governments). However, these factors of risk remain debatable and have yet to be proven. Atmospheric pollution, which may have decreased during lockdown, is a controversial factor of risk since it depends on the type of particule studied and the trimester of exposure (25, 26). With respect to rest, a systematic review by Cochrane (27) published in 2015, did not find evidence to show that bedrest reduced prematurity, on the contrary it may have negative effects such as an increase in demineralisation of bone and deconditioning during exercise or an increased risk of deep vein thrombosis (28). With respect to maternal stress, this is a subjective element with different definitions according to the studies so it is difficult to establish an association with perinatal issues such as prematurity. While it is qualified as a risk factor some studies do not report any difference and even report a decrease in prematurity (29). There also exists a hypothesis suggesting that stressful events do not have the same impact when experienced in the first, second or third trimester of pregnancy, with a higher degree of stress at the beginning of pregnancy (30).

It should be noted that preventive measures exist to reduce prematurity (31, 32). There are three types: primary prevention that concerns all women, secondary prevention to reduce and eliminate already existing risks and tertiary prevention to improve the outcome of infants born prematurely. Tertiary prevention has been the most developed in recent years, with the set up of networks of organisations providing perinatal care and health care to mothers and their newborns in adapted maternities, of antenatal corticosteroid therapy use and administration of magnesium sulphate.

## 5. Conclusion

The objective of our study was to examine the consequences of lockdown in France due to the SARS-CoV-2 pandemic on prematurity before 37 weeks of gestation in the level III maternity of the Nice University Hospital. We did not find evidence of an association between lockdown and prematurity, which is in agreement with published meta-analyses. Certain factors of risk such as atmospheric pollution, rest and maternal stress that were discussed during lockdown are debatable and their involvement remains to be demonstrated. The identification of the factors of risk of prematurity and the preventive measures are still a major public health issue.

## Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

## Author contributions

ML, KL, and BF-G: have made a substantial contribution to the concept of the article and acquisition of date for the article KL: have made a substantial contribution to the interpretation and analysis of data for the article MM, SE, AH-B, and IG-R: revised the article for the important intellectual content and approved the version to be published. All authors contributed to the article and approved the submitted version.

# Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

# Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

## References

- 1. Vogel JP, Chawanpaiboon S, Moller AB, Watananirum K, Bonet M, Lumbiganon P. The global epidemiology of preterm birth. *Best Pract Res Clin Obstet & Gynaecol.* (2018) 52:3–12. doi: 10.1016/j.bpobgyn.2018.04.003
- 2. Elysée. Adresse aux Français. (2020). Available at: https://www.elysee.fr/emmanuelmacron/2020/03/16/adresse-aux-francais-covid19 (Accessed March 16, 2020).
- 3. Starr R, De Jesus O, Shah SD, Borger J. Periventricular and intraventricular hemorrhage. USA: Int StatPearls (2022).

<sup>4.</sup> Muller MJ, Paul T, Seeliger S. Necrotizing enterocolitis in premature infants and newborns. J Neonatal Perinatal Med. (2016) 9(3):233–42. doi: 10.3233/NPM-16915130

<sup>5.</sup> Vaccaro C, Mahmoud F, Aboulatta L, Aloud B, Eltonsy S. The impact of COVID-19 first wave national lockdowns on perinatal outcomes: a rapid review and metaanalysis. *BMC Pregnancy Childbirth*. (2021) 21:676. doi: 10.1186/s12884-021-04156-y

<sup>6.</sup> Chmielewska B, Barrat I, Townsend R, Kalafat E, van der Meulen J, Gurol-Urganci I, et al. Effects of the COVID-19 pandemic on maternal and perinatal

outcomes: a systematic review and meta- analysis. Lancet Glob Health. (2021) 9: e759-72. doi: 10.1016/S2214-109X(21)00079-6

7. Yang J, D'Souza R, Kharrat A, Fell D, Snelgrove J, Shah PS. COVID-19 pandemic and population-level pregnancy and neonatal outcomes in general population: a living systematic review and meta-analysis (update#2: November 20, 2021). Acta Obstet Gynecol Scand. (2022) 101:273–92. doi: 10.1111/aogs.14318

8. Garabedian C, Dupuis N, Vayssière C, Bussières L, Ville Y, Renaudin B, et al. Impact of COVID-19 lockdown on preterm births, low birthweights and stillbirths: a retrospective cohort study. *JCM*. (2021) 10:5649. doi: 10.3390/jcm10235649

9. Arnaez J, Ochoa-Sangrador C, Caserio S, Gutiérrez EP, del Pilar Jiménez M, Castanon L, et al. Lack of changes in preterm delivery and stillbirths during COVID-19 lockdown in a European region. *Eur J Pediatr.* (2021) 180:1997–2002. doi: 10.1007/s00431-021-03984-6

10. Pasternak B, Neovius M, Soderling J, Ahlberg M, Norman M, Ludvigsson J, et al. Preterm birth and stillbirth during the COVID-19 pandemic in Sweden: a nationwide cohort study. *Ann Intern Med.* (2021) 174:873–5. doi: 10.7326/M20-6367

11. Mor M, Kugler N, Jauniaux E, Betser M, Wiener Y, Cuckle H, et al. Impact of the COVID-19 pandemic on excess perinatal mortality and morbidity in Israel. *Am J Perinatol.* (2021) 38:398–403. doi: 10.1055/s-0040-1721515

12. Wood R, Sinnot C, Goldfarb I, Clapp M, McElrath T, Little S. Preterm birth during the coronavirus disease 2019 (COVID-19) pandemic in a large hospital system in the United States. *Obstet Gynecol.* (2021) 137:403–4. doi: 10.1097/AOG. 000000000004237

13. Khalil A, von Dadelszen P, Draycott T, Ugwumadu A, O'Brien P, Magee L. Change in the incidence of stillbirth and preterm delivery during the COVID-19 pandemic. JAMA. (2020) 324(7):705–6. doi: 10.1001/jama.2020.12746

14. Cheung PY, Alshaikh B, Yang C. COVID-19 Pandemic: different associative relationships of city lockdown with preterm births in three cities—an ecological study. *Front Pediatr.* (2021) 9:644771. doi: 10.3389/fped.2021.644771

15. Philip RK, Purtill H, Reidy E, Daly M, Imcha M, McGrath D, et al. Unprecedented reduction in births of very low birthweight (VLBW) and extremely low birthweight (ELBW) infants during the COVID- 19 lockdown in Ireland: a "natural experiment" allowing analysis of data from the prior two decades. *BMJ Glob Health*. (2020) 5(9):e003075. doi: 10.1136/bmjgh-2020-003075

16. Hedermann G, Hedley PL, Baekvad-Hansen M, Hjalgrim H, Rostgaard K, Poorisrisak P, et al. Danish premature birth rates during the COVID-19 lockdown. *Arch Dis Child Fetal Neonatal Ed.* (2021) 106:93–5. doi: 10.1136/archdischild-2020-319990

17. Ranjbar F, Allahqoli L, Ahmadi S, Mousavi R, Gharacheh M, Eshraghi N, et al. Changes in pregnancy outcomes during the COVID-19 lockdown in Iran. *BMC Pregnancy Childbirth*. (2021) 21:577. doi: 10.1186/s12884-021-04050-7

18. Matheson A, McGannon CJ, Malhotra A, Palmer KR, Stewart AE, Wallace EM, et al. Prematurity rates during the coronavirus disease 2019 (COVID-19) pandemic lockdown in Melbourne, Australia. *Obstet Gynecol.* (2021) 137:405–7. doi: 10.1097/AOG.000000000004236

19. Huseynova R, Bin Mahmoud L, Abdelrahim A, Al Hemaid M, Almuhaini MS, Jaganathan PP, et al. Prevalence of preterm birth rate during COVID-19 lockdown in a tertiary care hospital, Riyadh. *Cureus.* (2021) 13(3):e13634. doi: 10.7759/cureus.13634

20. De Curtis M, Villani L, Polo A. Increase of stillbirth and decrease of late preterm infants during the COVID-19 pandemic lockdown. *Arch Dis Child Fetal Neonatal Ed.* (2021) 106:456. doi: 10.1136/archdischild-2020-320682

21. Been JV, Burgos Ochoa L, Bertens LCM, Schoenmakers S, Steegers EAP, Reiss IKM. Impact of COVID-19 mitigation measures on the incidence of preterm birth: a national quasi-experimental study. *Lancet Public Health*. (2020) 5:e604–11. doi: 10.1016/S2468-2667(20)30223-1

22. Kirchengast S, Hartmann B. Pregnancy outcome during the first COVID 19 lockdown in Vienna, Austria. *Int J Environ Res Public Health*. (2021) 18:3782. doi: 10.3390/ijerph18073782

23. Calvert C, Brockway MM, Zoega H, Miller JE, Been JV, Amegah AK, et al. Changes in preterm birth and stillbirth during COVID-19 lockdowns in 26 countries. *Nat Hum Behav.* (2023) 7(4):529-44. doi: 10.1038/s41562-023-01522-y

24. Yao XD, Zhu LJ, Yin J, Wen J. Impact of COVID-19 pandemic on preterm birth: a systematic review and meta-analysis. *Public Health*. (2022) 213:127–34. doi: 10.1016/ j.puhe.2022.10.015

25. DeFranco E, Moravec W, Xu F, Hall E, Hossain M, Haynes EN. Exposure to airborne particulate matter during pregnancy is associated with preterm birth: a population-based cohort study. *Environ Health.* (2016) 15:6. doi: 10.1186/s12940-016-0094-3

26. Johnson S, Bobb JF, Ito K, Savitz DA, Elston B, Shmool JLC, et al. Ambient fine particulate matter, nitrogen dioxide, and preterm birth in New York City. *Environ Health Perspect.* (2016) 124:1283–90. doi: 10.1289/ehp.1510266

27. Sosa CG, Althabe F, Belizán JM, Bergel E. Bed rest in singleton pregnancies for preventing preterm birth. *Cochrane Database Syst Rev.* (2015) 3:CD003581. doi: 10. 1002/14651858.CD003581.pub3

28. Rozenberg P. Prise en charge des grossesses à risque: quelle place pour le repos? Coll Natl Gynécol Obstét Français. (2014) 23:97–104. doi: 10.1016/j.vsf.2015.11.007

29. Omer H, Friedlander D, Palti Z, Shekel I. Life stresses and premature labor: real connection or artifactual findings? *Psychosom Med.* (1986) 48:362–9. doi: 10.1097/00006842-198605000-00006

30. Gallois T, Wendland J, Tordjman S. Effets du stress prénatal sur le fœtus et les données périnatales: une revue critique de la littérature. *Évol Psychiatr.* (2012) 77:291-301. doi: 10.1016/j.evopsy.2012.01.006

31. Matei A, Saccone G, Vogel JP, Armson AB. Primary and secondary prevention of preterm birth: a review of systematic reviews and ongoing randomized controlled trials. *Eur J Obstet Gynecol Reprod Biol.* (2019) 236:224–9. doi: 10.1016/j.ejogrb.2018.12.022

32. Iams JD, Romero R, Culhane JF, Goldenberg RL. Primary, secondary, and tertiary interventions to reduce the morbidity and mortality of preterm birth. *Lancet.* (2008) 371:164–75. doi: 10.1016/S0140-6736(08)60108-7